

Press release**Launch of the public offering of Genomtec shares to raise funds for the finalization of the M&A process and the commercialization of Genomtec ID and OncoSNAAT® technologies**

Wrocław, May 19, 2026, Genomtec S.A., a molecular diagnostics company (WSE ticker: GMT), announced the launch of a public offering of shares by its principal shareholder, 5HT Family Foundation, through an accelerated bookbuilding process (ABB). The proceeds from the offering will then be reinvested in the company's balance sheet, as they will be fully reinvested in newly issued shares – 2 million new series R shares and up to 204,000 series S shares. The relevant consents were granted by the company's shareholders at the Extraordinary General Meeting on April 13th.

"We intend to use the funds raised from the new share issue primarily to support the M&A process and further implement key development projects, in particular testing the diagnostic parameters of the 3-plex variant of the Genomtec ID platform in the context of potential M&A transactions, as well as continuing projects that have already received grant funding. In this regard, we plan to design and manufacture prototypes of reaction cards and the OncoSNAAT® analyzer for research purposes, as well as support a project utilizing AI solutions to develop primer sets for molecular diagnostics. We hope that these activities will allow us to successfully complete the M&A process and deliver unique value to our shareholders."— says Miron Tokarski, President of the Management Board and co-founder of Genomtec SA

As part of the transaction, on March 17th of this year, the Company entered into an investment agreement with a significant shareholder, 5HT Family Foundation, under which the Shareholder agreed to conduct a public offering of up to 2 million existing shares, including those borrowed from Genomtec's CEO, Miron Tokarski, and Genomtec's co-founder, Małgorzata Małodobrej-Mazur. All proceeds will be used to acquire newly issued Series R shares. Genomtec will thus obtain funds from the sale of Series R shares, which will be used to support the commercialization of projects as part of the M&A process conducted by Genomtec.

The company's flagship project is the Genomtec ID® mobile diagnostic system, which consists of an analyzer and a reaction card with integrated genetic tests. The Genomtec ID® platform is based on the proprietary SNAAT® solution and stands out from the competition for its mobility, speed, and ability to simultaneously diagnose multiple pathogens at the point of care. The OncoSNAAT® project, in turn, is a technology for detecting genetic changes occurring in cancer, which is crucial in personalized medicine, for example, when selecting targeted oncology treatments.

Legal disclaimer

This publication is for informational purposes only and does not serve to promote, directly or indirectly, the Company's share offering by any shareholder. It does not constitute promotional material or advertising prepared or published by the Company for the purpose of promoting or subscribing to the Company's shares, or encouraging, directly or indirectly, the purchase of the Company's shares. This publication does not constitute a prospectus or any other memorandum, information document, or offering document. No prospectus will be issued

in connection with the matters covered by this publication, and no prospectus is required. This publication does not contain or constitute an offer to sell or subscribe for securities, nor a solicitation of an offer to purchase securities, nor a solicitation/recommendation to purchase securities. It does not constitute an investment recommendation within the meaning of applicable law and, under no circumstances, constitutes the basis for making a decision to purchase the Company's securities. This publication and the information contained herein are restricted and not for publication, announcement, distribution or transmission, directly or indirectly, in whole or in part, in or into the United States of America, Australia, Canada, South Africa, Japan or any other country where such publication, announcement, distribution or transmission would be unlawful.

About Genomtec:

Genomtec is a MedTech company specializing in developing advanced technologies in the field of genetic diagnostics. The company's flagship project is the Genomtec ID mobile diagnostic system. The system allows for quick and precise molecular analysis outside the laboratory environment, without the need for qualified laboratory personnel. The solution utilizes microfluidic technology and proprietary, patented isothermal technology SNAAT®. Genomtec's technology is protected by nearly 20 patents in Europe, the US, and Japan, among others, and the company has over 30 patent applications pending.

The company has EU CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory tract infections.

The company is headquartered in Wrocław. Genomtec also has a presence in the UK, where an office and part of its international research and engineering team are located.

More information is available on the company's website: www.genomtec.com

Media contact:

Michał Wierzchowski

Tel.: +48 531 613 067

michal.wierzchowski@ccgroup.pl

Contact for investors:

Agata Dzieciółowska

Tel.: +48 606 205 119

agata.dzieciolowska@ccgroup.pl